# Rigel Pharmaceuticals Inc: overview

RIGL · Nasdaq · CIK 1034842 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rigl.md) · [Financials](/companies/rigl/financials.md) · [Filings](/companies/rigl/filings.md) · [Insiders](/companies/rigl/insiders.md)

Latest reported revenue: [$78.7m](/filings/0001034842-26-000052.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 4, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001034842-26-000052).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [55.3](/filings/0001104659-25-106268.md) | [57.6 d](/filings/0001034842-26-000015.md) | [53.3](/filings/0001034842-26-000032.md) | [102](/filings/0001034842-26-000052.md) | [69.5](/filings/0001104659-25-106268.md) | [69.8 d](/filings/0001034842-26-000015.md) | [58.8](/filings/0001034842-26-000032.md) | [78.7](/filings/0001034842-26-000052.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [25.4%](/filings/0001104659-25-106268.md) | [28.9% d](/filings/0001034842-26-000015.md) | [23.9%](/filings/0001034842-26-000032.md) | [60.1%](/filings/0001034842-26-000052.md) | [40.9%](/filings/0001104659-25-106268.md) | [33.2% d](/filings/0001034842-26-000015.md) | [20.2%](/filings/0001034842-26-000032.md) | [30.0%](/filings/0001034842-26-000052.md) |
| Net margin | % | [22.5%](/filings/0001104659-25-106268.md) | [24.9% d](/filings/0001034842-26-000015.md) | [21.5%](/filings/0001034842-26-000052.md) | [58.6%](/filings/0001034842-26-000052.md) | [40.2%](/filings/0001104659-25-106268.md) | [384.0% d](/filings/0001034842-26-000015.md) | [14.7%](/filings/0001034842-26-000052.md) | [22.0%](/filings/0001034842-26-000052.md) |
| Diluted EPS | $ per share | [0.70](/filings/0001104659-25-106268.md) | not reported | [0.63](/filings/0001034842-26-000032.md) | [3.28](/filings/0001034842-26-000052.md) | [1.46](/filings/0001104659-25-106268.md) | not reported | [0.44](/filings/0001034842-26-000032.md) | [0.88](/filings/0001034842-26-000052.md) |
| Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [149](/filings/0001558370-24-002475.md) | [120](/filings/0001558370-25-002169.md) | [117](/filings/0001034842-26-000015.md) | [179](/filings/0001034842-26-000015.md) | [294](/filings/0001034842-26-000015.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(8.4%)](/filings/0001558370-24-002475.md) | [(46.2%)](/filings/0001558370-25-002169.md) | [(17.5%)](/filings/0001034842-26-000015.md) | [13.5%](/filings/0001034842-26-000015.md) | [42.6%](/filings/0001034842-26-000015.md) |
| Net margin | % | [(12.0%)](/filings/0001558370-24-002475.md) | [(48.7%)](/filings/0001558370-25-002169.md) | [(21.5%)](/filings/0001034842-26-000015.md) | [9.8%](/filings/0001034842-26-000015.md) | [124.7%](/filings/0001034842-26-000015.md) |
| Diluted EPS | $ per share | [(0.11)](/filings/0001558370-24-002475.md) | [(3.44)](/filings/0001558370-25-002169.md) | [(1.44)](/filings/0001034842-26-000015.md) | [0.99](/filings/0001034842-26-000015.md) | [19.48](/filings/0001034842-26-000015.md) |
| Free cash flow | $m | [5.3](/filings/0001558370-24-002475.md) | [(74.2)](/filings/0001558370-25-002169.md) | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/rigl/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $75.9m | 1,939,818 |  | Added +170,911 |
| [Soleus Capital Management, L.P.](/funds/1802630.md) | 2026-06-30 | $72.1m | 1,843,504 |  | Added +1,833,504 |
| [ARMISTICE CAPITAL, LLC](/funds/1601086.md) | 2026-06-30 | $65.4m | 1,672,000 |  | Added +392,000 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $40.7m | 1,039,994 |  | Reduced −80,244 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $30.7m | 785,107 |  | Added +20,914 |
| [AMERICAN CENTURY COMPANIES INC](/funds/748054.md) | 2026-06-30 | $29.0m | 741,718 |  | Added +197,287 |
| [D. E. Shaw & Co., Inc.](/funds/1009207.md) | 2026-06-30 | $21.2m | 542,539 |  | Added +96,861 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $18.9m | 483,175 |  | Added +42,549 |
| [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $14.4m | 367,393 |  | Reduced −230,985 |
| [CM Management, LLC](/funds/1841857.md) | 2026-06-30 | $9.8m | 250,000 |  | Added +15,000 |

## Recent filings

[All 940 filings](/companies/rigl/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-04 | 16:10 ET | [8-K](/filings/0001034842-26-000053.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001034842-26-000053 |
| 2026-08-04 | 16:06 ET | [10-Q](/filings/0001034842-26-000052.md) | Quarterly report, period 2026-06-30 | 0001034842-26-000052 |
| 2026-07-01 | 16:11 ET | [8-K](/filings/0001034842-26-000045.md) | 5.02 Departure or appointment of officers or directors | 0001034842-26-000045 |
| 2026-06-17 | 16:05 ET | [8-K](/filings/0001034842-26-000043.md) | 2.01 Completion of an acquisition or disposition | 0001034842-26-000043 |
| 2026-05-20 | 16:10 ET | [8-K](/filings/0001034842-26-000041.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0001034842-26-000041 |
| 2026-05-12 | 17:24 ET | [8-K](/filings/0001034842-26-000038.md) | 1.01 Entry into a material agreement | 0001034842-26-000038 |
| 2026-05-05 | 16:08 ET | [8-K](/filings/0001034842-26-000033.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001034842-26-000033 |
| 2026-05-05 | 16:05 ET | [10-Q](/filings/0001034842-26-000032.md) | Quarterly report, period 2026-03-31 | 0001034842-26-000032 |
| 2026-04-21 | 16:18 ET | [8-K](/filings/0001034842-26-000027.md) | 1.02 Termination of a material agreement | 0001034842-26-000027 |
| 2026-04-03 | 16:01 ET | [DEF 14A](/filings/0001034842-26-000023.md) | Proxy statement, period 2026-05-14 | 0001034842-26-000023 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001034842-26-000015.md), filed Mar 3, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/6bc5d9cf-1363-4108-9728-643f7db16db3)

## About the filer

- CIK: 1034842
- Tickers: RIGL
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:30 ET. No prices; not investment advice.